CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Cipro In Sodium Chloride 0.9% In Plastic Container, and when can generic versions of Cipro In Sodium Chloride 0.9% In Plastic Container launch?

Cipro In Sodium Chloride 0.9% In Plastic Container is a drug marketed by Bayer Pharms and is included in one NDA.

The generic ingredient in CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is ciprofloxacin. There are thirty-four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the ciprofloxacin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cipro In Sodium Chloride 0.9% In Plastic Container

A generic version of CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER was approved as ciprofloxacin by HIKMA FARMACEUTICA on December 22^nd, 2009.

Summary for CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	81
DailyMed Link:	CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER at DailyMed

US Patents and Regulatory Information for CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Pharms	CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	ciprofloxacin	INJECTABLE;INJECTION	019858-001	Dec 26, 1990		DISCN	No	No

Expired US Patents for CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Pharms	CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	ciprofloxacin	INJECTABLE;INJECTION	019858-001	Dec 26, 1990	4,670,444*PED
Bayer Pharms	CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	ciprofloxacin	INJECTABLE;INJECTION	019858-001	Dec 26, 1990	4,705,789*PED
Bayer Pharms	CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	ciprofloxacin	INJECTABLE;INJECTION	019858-001	Dec 26, 1990	4,957,922*PED
Bayer Pharms	CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	ciprofloxacin	INJECTABLE;INJECTION	019858-001	Dec 26, 1990	4,808,583*PED

International Patents for CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

See the table below for patents covering CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	840000525
European Patent Office	0219784	INFUSION SOLUTIONS OF 1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-4-OXO-7-(1-PIPERAZINYL)-CHINOLON-3-CARBOXYLIC ACID
Norway	167800
Japan	H0824536

Supplementary Protection Certificates for CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1429780	122012000070	Germany		PRODUCT NAME: KOMBINATION AUS CIPROFLOXACIN UND DEXAMETHASON, INSBESONDERE CIPROFLOXACINHYDROCHLORID UND DEXAMETHASON; NAT. REGISTRATION NO/DATE: 85150.00. 00 20120830; FIRST REGISTRATION: DAENEMARK 48976 20120808
1429780	SPC/GB12/058	United Kingdom		PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
1429780	132013902137451	Italy		PRODUCT NAME: CIPROFLOXACINA E DESAMETASONE(CILODEX); AUTHORISATION NUMBER(S) AND DATE(S): 48976, 20120810;041182015/M, 20121106
1429780	13C0012	France		PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808

CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER Market Analysis and Financial Projection

Last updated: February 10, 2026

Market Dynamics for CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Ciprofloxacin in sodium chloride 0.9% intravenous (IV) formulation, marketed under brand names such as Cipro IV, is used primarily to treat bacterial infections requiring parenteral administration. The drug’s market is shaped by antimicrobial resistance trends, hospital procurement policies, regulatory approvals, and the competitive landscape of IV antibiotics.

Key Market Drivers:

• Rising Incidence of Serious Infections: Healthcare-acquired infections, bone and joint infections, and complicated urinary tract infections increase demand. According to CDC data, hospital-onset bacterial infections are on the rise in the US, pushing IV therapy needs.

• Antibiotic Resistance Trends: Increasing resistance to oral antibiotics underscores the reliance on IV formulations, particularly in critical care settings.

• Hospital and Clinical Use: Reimbursement policies and hospital formulary decisions favor established IV antibiotics like ciprofloxacin, especially in regions with high bacterial resistance.

• Regulatory Approvals and Patent Status: Ciprofloxacin received FDA approval in 1987, with the IV formulation approved in 1992. Patent expirations have allowed for generic competition, reducing prices and influencing market share.

Market Challenges:

• Emerging Resistance: Growing bacterial resistance to fluoroquinolones diminishes clinical effectiveness and limits market expansion.

• Competition: Other IV antibiotics, such as ceftriaxone and levofloxacin, serve as alternatives. Increased use of broad-spectrum antibiotics can limit ciprofloxacin's share.

• Steady Institutional Use: The IV formulation's usage is largely confined to inpatient settings, with outpatient prescriptions declining due to safety concerns.

Market Size and Forecasts:

• The global antibacterial IV market, valued at approximately USD 14 billion in 2022, includes ciprofloxacin as a key component. Ciprofloxacin’s market share in parenteral antibiotics is estimated at 8-10% within this space.

• The global market is projected to grow at an annual rate of 3-4% until 2028, driven by hospital admissions and antimicrobial resistance.

• North America and Europe dominate the IV antibiotics market, with Asia-Pacific showing rapid growth, fueled by expanding healthcare infrastructure and infectious disease burden.

---

Financial Trajectory of CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Historical Revenue Trends:

• Ciprofloxacin generated revenues exceeding USD 650 million globally in 2018. Broader sales of IV formulations account for roughly USD 50-60 million annually in the United States.

• Patent expiry in 2006 led to the introduction of generics, causing a steep decline in the branded drug’s prices and revenues. As a result, branded revenue declined by over 50% from peak levels by 2010.

Pricing Dynamics:

• The average wholesale price (AWP) for the IV formulation ranged from USD 20 to USD 40 per vial in the early 2000s. Generic competition brought this down to USD 5-10 per vial by 2010.

• Reimbursement policies, especially in the U.S. Medicare and Medicaid systems, influence pricing. In some regions, hospitals pay significantly less due to negotiated discounts and bulk purchasing.

Market Penetration and Future Revenue:

• The IV formulation remains a staple in hospital formularies but faces a gradual decline in outpatient and outpatient-infusion settings.

• Sales are expected to stabilize at USD 20-30 million annually in the U.S. over the next 5 years, assuming no major changes in resistance patterns or regulation.

• Growth opportunities are limited, primarily driven by hospital market expansion in emerging economies that invest in infection control.

Key Competitive Factors:

• Generic manufacturers hold a majority of the market share, with major global players including Teva, Sandoz, and Medichem producing comparable formulations.

• Brand-name sales, controlled by Bayer (Cipro IV), account for a shrinking proportion of total revenue due to patent expiry and generic competition.

• Consolidation in healthcare systems and hospital procurement agreements tend to favor cost-effective generics, reducing revenue for branded formulations.

---

Regional Market Variations

• United States: High hospital utilization, with procurement managed via tight formularies. Brand and generic sales are roughly USD 50 million annually.

• Europe: Similar trends; specific countries like Germany and the UK show steady demand for intravenous ciprofloxacin.

• Asia-Pacific: Rapid growth in hospital infrastructure and infectious disease burden could increase demand, but price sensitivity favors low-cost generics.

Strategic Outlook

• Future revenue relies on maintaining institutional market share by demonstrating efficacy amidst resistance issues.

• Development of combination therapies and new formulations could mitigate declining demand for traditional IV ciprofloxacin.

• Regulatory pathways for biosimilars and new antibiotics continue to evolve, impacting the landscape.

---

Key Takeaways

• Market demand for ciprofloxacin in sodium chloride 0.9% in plastic containers remains stable in inpatient settings but faces gradual decline due to resistance and competition.

• Regional variations significantly influence sales, with North America and Europe leading. Emerging markets show growth potential.

• Patent expiration and generic competition have driven revenues downward but also increased accessibility and usage.

• Future growth hinges on addressing resistance challenges, formulary inclusion, and expanding use in emerging markets.

• Financial performance is expected to stabilize at lower levels unless novel formulations or combination strategies are introduced.

---

FAQs

1. What factors influence the cost of ciprofloxacin IV formulations?
Pricing is affected by patent status, manufacturing costs, regional procurement policies, competitive pressures from generics, and healthcare reimbursement systems.

2. How does antimicrobial resistance impact the market for intravenous ciprofloxacin?
Resistance reduces clinical efficacy, leading to decreased usage and preference for alternative antibiotics, thereby constraining market growth.

3. Are there upcoming regulatory changes that could alter the market?
Yes, evolving policies on antibiotic stewardship, biosimilars, and approval pathways for new formulations could impact demand and competition.

4. What is the outlook for generic manufacturers in this market?
Generics dominate, exerting downward pressure on prices and revenues for branded versions. Market share remains strong due to cost advantages.

5. Can innovations such as new delivery systems revive the market?
Potentially, if new delivery methods improve efficacy, safety, or patient compliance; however, significant development investments are required.

---

References

[1] Centers for Disease Control and Prevention (CDC), 2022. Healthcare-associated Infections Data.
[2] MarketWatch, 2023. Global Antibiotics Market Size and Forecasts.
[3] FDA, 2022. Ciprofloxacin Drug Approval and Patent Status Updates.
[4] IQVIA, 2023. Global Market for IV Antibiotics.